A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy.
Filip K Krag KnopShweta UrvaMallikarjuna RettigantiCharles T BensonWilliam C RoellKieren J MatherAxel HauptEdward John PrattPublished in: Diabetes, obesity & metabolism (2024)